Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Key Eligibility Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Confirmed recurrent Stage IV NSCLC which progressed while on treatment with EGFR TKI * Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) * Documented evidence of an EGFR mutation known to be associated with an EGFR TKI sensitivity * No T790M mutation or small cell transformation including an assessment from tumor biopsy obtained while on or subsequent to the most recent EGFR TKI therapy * Acceptable laboratory results as indicated by protocol * Acceptable cardiac function as indicated by protocol Key Exclusion Criteria: * Receiving medication that prolongs QT interval, with a risk of causing Torsades de Pointes (TdP) unless ECG meets inclusion criteria while on a stable dose of the medication * Family history of long corrected QT interval (QTc) syndrome * Symptomatic central nervous system (CNS) lesions * Radiation therapy within 2 weeks prior to the first dose of study medication * Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication * Concurrent active malignancy requiring systemic treatment * Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection (e.g., tuberculosis, viral hepatitis, human immunodeficiency virus \[HIV\]), recent (within 6 months) myocardial infarction or unstable angina, congestive heart failure, poorly-controlled hypertension or diabetes, concurrent active malignancy, or psychiatric condition that may interfere with the patient's ability to follow study procedures * Pregnant or breast-feeding